United States newsroom

Myrbetriq is the first and only beta-3 adrenergic agonist indicated for the treatment of overactive bladder NORTHBROOK, Ill., June 28, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a...

Event Kicks Off Astellas' Annual Changing Tomorrow Day Volunteer Initiative KISSIMMEE, Fla., June 13, 2012 /PRNewswire/ -- Give Kids The World Village (GKTW) will host its largest single...

Japanese Pharmaceutical Company Expands in Glenview GLENVIEW, Ill. – June 4, 2012. Governor Pat Quinn today joined Astellas executives and more than 1,000 employees to open the company’s new...

Dose-Escalation Completed and Preliminary Antitumor Activity Observed Santa Monica, CA and Bothell, WA – June 4, 2012 – Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and...

On May 21, 2012, the American Urological Association (AUA) issued the first guidelines specific to the diagnosis and treatment of overactive bladder (OAB) in the U.S. Astellas supports these new...

DEERFIELD, Ill., April 5, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the Reproductive...

DEERFIELD, Ill., Feb. 21, 2012 /PRNewswire/ -- Astellas announces Charlotte M. E. Kremer, MD, MBA has joined the company as the head of one of the Company's newest organizations – Global Medical...

CARMEL, Calif. and DEERFIELD, Ill., Feb. 7, 2012 /PRNewswire/ -- Today, Science Buddies and Astellas USA Foundation ("Foundation") announced initiation of the Science Buddies-Astellas Rosalind...

SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...

Frank P. Hudson as Vice President of Finance Wolfgang Noe, Ph.D., as Vice President, Process Sciences and Manufacturing SANTA MONICA, Calif., Dec. 1, 2011 /PRNewswire/ -- Agensys, Inc....

More than 500 Astellas Employees Tackle Improvement Projects as Part of Company's Commitment to Service DEERFIELD, Ill., Sept. 23, 2011 /PRNewswire/ -- More than 500 employees from Astellas Pharma...

DEERFIELD, IL, September 15, 2010 – On January 1, 2011, the Donate Life float will roll through the streets of Pasadena reminding millions of viewers of the Rose Parade® to “Seize the Day”...

DEERFIELD, Ill., Aug. 15, 2011 /PRNewswire/ -- Astellas US, LLC ("Astellas") recently named Percival Barretto-Ko as Senior Vice President, Corporate Strategy and Government Affairs, a new position...

WHITEHOUSE STATION, N.J. and DEERFIELD, Ill., July 26, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Astellas US LLC ("Astellas"), the U.S. subsidiary of...

DEERFIELD, Ill., June 6, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data...

SOUTH SAN FRANCISCO, Calif. – June 2, 2011 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. (“Astellas”), today announced results of...

DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick...

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the...

DEERFIELD, Ill., May 3, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc. ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, welcomes four seasoned industry leaders...

EURTAC is the First Phase III Study to Show Progression-Free Survival Benefit of First-Line Tarceva in a Western Population with Advanced Lung Cancer With EGFR Mutations SOUTH SAN FRANCISCO,...

Tokyo, – January 10, 2011 – Astellas Pharma Inc. (TSE: 4503) announced today that it has engaged Citigroup Global Markets Inc. to conduct, in conjunction with executive management, a review of...

48 Middle and Secondary School Science Teachers From Across the Country to Begin Year-long Professional Development Journey ARLINGTON, Va. — November 15, 2010 — The National Science Teachers...

TOKYO, Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that Donald B. Rice, PhD. will retire from Astellas...

CHICAGO and DEERFIELD, Ill., Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a research-based pharmaceutical company based in Deerfield, Ill., is pleased to donate 150 used...

K-12 Science Teachers and Parents Also Agree Outside Mentors and Use of Technology Resources Can Play an Important Role CHICAGO AND DEERFIELD, IL, October 28, 2010 – A new national survey...

Phase IV Data Meets Primary Endpoint PHILADELPHIA, PA, September 25, 2010 – Today Astellas Pharma US, Inc., (“Astellas”) announced results of a Phase IV study showing Lexiscan®...

PHILADELPHIA, PA, September 24, 2010 - Today Astellas Pharma US, Inc. ("Astellas") announced the Launch of the Appropriate Use Criteria (AUC) for Cardiac Radionuclide Imaging application (app) for...

DEERFIELD, IL, September 15, 2010 – Astellas Pharma US, Inc. has announced the winners of the second 2010 Transplant Scholars Awards, which awarded a dozen $5,000 educational scholarships to...

SANTA MONICA, Calif.- Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate...

Astellas Launches Science WoRx Program Aimed to Ignite Students' Passion for Science and Cultivate the Next Generation of Scientists Today Astellas Pharma US, Inc. ("Astellas") announced the...

Company Breaks Ground in Glenview, Will Create 150 Jobs GLENVIEW, IL – April 29, 2010. Governor Pat Quinn today announced an approximately $4 million investment package to assist Astellas Pharma...

MELVILLE, N.Y., Apr 29, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...

MELVILLE, N.Y., Apr 26, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing...

First Maintenance Therapy Approved For a Broad Patient Population Including Squamous and Non- Squamous Histology MELVILLE, N.Y., Apr 16, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:...

Survey Reveals Pervasive Donation Myths RICHMOND, Va. (April 5, 2010) – According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have...

MELVILLE, N.Y., Mar 19, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva(R) (erlotinib), Roche, informed OSI that the...

MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jan 15, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG;...

Innovative Needle-Free Delivery System Provides Fast Migraine Relief SAN DIEGO, Calif. and DEERFIELD, Ill., January 13, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical...

Fourth Quarter U.S. Tarceva Sales Increased 17% on Prior Year to $137 Million Total Global Tarceva Sales for 2009 Top $1.2 Billion MELVILLE, N.Y., Jan 12, 2010 (BUSINESS WIRE) -- OSI...

MELVILLE, N.Y., Dec 29, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065,...

GAITHERSBURG, Md., Dec 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced...

MOTTEP Honors Astellas for Commitment to Transplant Community Deerfield, IL (December 7, 2009) – Astellas Pharma US, Inc. was inducted into the National Minority Organ Tissue Transplant...

MELVILLE, N.Y., Nov 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva(R)...

SOUTH SAN FRANCISCO, CA and DEERFIELD, IL – November 5, 2009 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in...

Vancouver, Canada and Deerfield, Illinois, USA, October 28, 2009 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”)...

Challenge to state of Illinois: 5,000 new organ donor registrations by the end of the year Deerfield, IL (October 26, 2009) – On November 1, 1999 Chicago Bears fans and the organ donation...

Data Published in Headache Highlights Bioequivalence, Safety and Ease of Use SAN DIEGO, CA and Deerfield, IL - (October 22, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical...

Study finds aminophylline needs comparable to current standard Minneapolis – October 2, 2009 – A new analysis reaffirms that Lexiscan® (regadenoson) Injection, the first selective A2A...

DEERFIELD, IL, September 22, 2009 – Astellas Pharma US, Inc. has announced the winners of the first annual Astellas Transplant Scholars Awards, $5,000 educational scholarships awarded to six...

Astellas provides ongoing support for greater Chicago-area science teachers to advance their career skills DEERFIELD, IL, September 21, 2009 – Astellas Pharma US, Inc. (“Astellas”), in...

MELVILLE, N.Y., Sep 17, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue...

DEERFIELD, IL, September 15, 2009 – Astellas Pharma US, Inc. today announced the winners of the Astellas Ride of a LifetimeSM 2010 contest. The contest asked transplant recipients to submit...

Chicago Mayor Richard M. Daley honored Astellas Pharma US, Inc. and two other Chicagoland companies on Aug. 14 at a ceremony in downtown Chicago with an award for their exemplary learning and...

Astellas Pharma US, Inc. ("Astellas") announced today an update regarding the status of the request for emergency relief and preliminary injunction from the U.S. Food and Drug Administration's...

In a ceremony recognizing "Chicago's 101 Best and Brightest Companies to Work For," Astellas Pharma US, Inc. won an Elite award for employee engagement and commitment by the National Association...

Unique needs of transplant patients require special care to preserve their gift of life Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has...

Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache SAN DIEGO, CA, and DEERFIELD, IL (August 3, 2009): Zogenix, Inc. (“Zogenix”), a privately held...

MELVILLE, N.Y., Aug 01, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib)...

MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jul 13, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. today announced that SATURN, a pivotal Phase III study of...

MELVILLE, N.Y.--(BUSINESS WIRE)--July 6, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...

MELVILLE, N.Y., Jun 15, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...

DEERFIELD, IL, June 4, 2009 – Astellas Pharma Global Development (“APGD”), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Betsy Garofalo has been hired...

DEERFIELD, IL, June 1, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Dan Dunham as the vice president of compliance. Dunham will be responsible for governance of the compliance...

Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy ORLANDO, Fla., May 30, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that...

Deerfield, IL (May 28, 2009) – The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf® (tacrolimus) in conjunction with mycophenolate...

DEERFIELD, IL, May 28, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Walt Johnston as vice president of marketing. Reporting directly to Patrick Shea, senior vice president of...

Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma Patients with an EGFR Mutation Achieved a 10 Fold Increase in the Time Patients Live...

Arginine vasopressin (AVP) receptor antagonist now available in new premixed formulation DEERFIELD, Illinois, April 1, 2009 — Astellas Pharma US, Inc. today announced the commercial availability...

Company continues path toward goal to become global category leader DEERFIELD, IL, April 1, 2009 – Astellas Pharma US, Inc. (“Astellas”) announced today Seigo Kashii, has been appointed...

Roche Submits Marketing Authorization Application for Approval of Tarceva as a First-line Maintenance Therapy in Europe MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19,...

MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 10, 2009-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals...

Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy MELVILLE, N.Y.--(BUSINESS WIRE)-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its U.S....

MELVILLE, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today's announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...

First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment SOUTH SAN FRANCISCO, Calif. & MELVILLE,...

Arginine vasopressin (AVP) receptor antagonist now approved in single-use premixed formulation DEERFIELD, Illinois, October 22, 2008 — Astellas Pharma US, Inc. today announced that the U.S. Food...

DEERFIELD, IL, October 14, 2008 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the fourth annual Astellas Ride of a Lifetime contest. Launched...

SOUTH SAN FRANCISCO, Calif. & MELVILLE, N.Y.-- Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin®

Greater Chicago-area science teachers gain resources to inspire young scientists in the classroom DEERFIELD, IL, October 1, 2008 – Astellas Pharma US, Inc. (“Astellas”) is pleased to...

Vancouver, Canada and Deerfield, Illinois, USA, August 11, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...

First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease Deerfield, Ill., June 24, 2008 – Astellas Pharma US, Inc. today announced the commercial availability...

First A2A Adenosine Receptor Agonist Approved for Use as Pharmacologic Stress Agent in Myocardial Perfusion Imaging PALO ALTO, Calif. and DEERFIELD, Ill., April 10 /PRNewswire-FirstCall/ -- CV...

Deerfield, Illinois and Vancouver, Canada, March 25, 2008 -- Astellas Pharma US, Inc. and its co-development partner Cardiome Pharma Corp. announced the first pivotal Phase III study evaluating...

MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 27, 2008--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it has filed with the U.S. Patent and Trademark Office an application to reissue its...

PRNewswire DEERFIELD, Ill. Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved their Supplemental New Drug Application (sNDA) seeking approval for...

Vancouver, Canada and Deerfield, Illinois, USA, January 21, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...

MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 14, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Tarceva® (erlotinib) has been listed on Japan's National Health Insurance (NHI) drug...

Vancouver, Canada and Deerfield, Illinois, USA, December 11, 2007 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...

ORLANDO, FL – November 7, 2007 – Astellas Pharma US, Inc. today announced that the investigational agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or...

Deerfield, Illinois – October 25, 2007 – Astellas Pharma US, Inc. today announced data demonstrating that VAPRISOL® (conivaptan hydrochloride injection) effectively raises serum sodium...

BASEL, Switzerland & MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 22, 2007--Roche and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Tarceva® (erlotinib) has been approved in Japan for...

SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued...

Educational program offers unique resources to empower transplant patients and their caregivers DEERFIELD, IL, October 17, 2007 – Astellas Pharma US, Inc., a leader in the field of...

Reaffirms 2007 Global Tarceva Sales Guidance MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 15, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided commentary today on third quarter U.S. Tarceva sales....

DEERFIELD, IL, October 11, 2007 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the third annual Astellas Ride of a Lifetime contest. Launched...

MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that the Company has received Notice of Final Determination from the US Patent and...

MELVILLE, N.Y., Sep 07, 2007 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of selected data from over 58 studies involving the Company's lead product,...

CHICAGO--(BUSINESS WIRE)--June 5, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of studies highlighting data involving the Company's lead product, Tarceva®, presented...

MELVILLE, N.Y.--(BUSINESS WIRE)--April 25, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding...

Arginine vasopressin (AVP) receptor antagonist now approved for the management of the two most common forms of potentially life-threatening sodium/water imbalance DEERFIELD, Illinois, March 2,...

Multi-award winning program offers resources to empower transplant patients and their caregivers DEERFIELD, IL, February 26, 2007 – Astellas Pharma US, Inc., a leader in the field of...